Hypoxia and activated VEGF/receptor pathway in multiple myeloma

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2831-2836

  Giatromanolaki, Alexandra ^a   Bai, M ^b   Margaritis, Dimitrios ^a   Bourantas, Konstantinos L ^b   Koukourakis, Michael I ^a   Sivridis, Efthimios ^a   Gatter, Kevin C ^c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Hypoxia; Multiple myeloma; VEGF; VEGFR2 KDR

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955795745     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Semenza GL, Shimoda LA and Prabhakar NR: Regulation of gene expression by HIF-1. Novartis Found Symp 272: 2-8, 2006.
2. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD and Maity A: EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1- dependent mechanisms. Cancer Res 66: 3197-3204, 2006.
3. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L: Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281: 25903-25914, 2006. (Pubitemid 44401796)
4. Toschi A, Lee E, Gadir N, Ohh M and Foster DA: Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 283: 34495-34499, 2008.
5. Lee BL, Kim WH, Jung J, Cho SJ, Park JW, Kim J, Chung HY, Chang MS and Nam SY: A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis 29: 44-51, 2008. (Pubitemid 351201740)
6. Klagsbrun M and D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7: 259-270, 1996. (Pubitemid 27200310)
7. Katoh O, Tauchi H, Kawaishi K, Kimura A and Satow Y: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55: 5687-5692, 1995.
8. Fox SB, Turley H, Cheale M, Blazquez C, Roberts H, James N, Cook N, Harris A and Gatter K: Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 202: 313-320, 2004.
9. Sher I, Adham SA, Petrik J and Coomber BL: Autocrine VEGF- A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124: 553-561, 2009.
10. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103: 3883-3889, 2004. (Pubitemid 38596309)
11. Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL and Gatter KC; Tumour and Angiogenesis Research Group: Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol 19: 701-707, 2006.
12. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC and Harris AL; Tumour Angiogenesis Research Group: Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24: 4301-4308, 2006. (Pubitemid 46630788)
13. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot DC et al: Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179: 80-88, 1996. (Pubitemid 26180086)
14. Alexandrakis MG, Passam FH, Dambaki C, Pappa CA and Stathopoulos EN: The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol 57: 856-60, 2004. (Pubitemid 39061436)
15. Bhatti SS, Kumar L, Dinda AK and Dawar R: Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 81: 649-56, 2006. (Pubitemid 44306822)
16. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR and Rajkumar SV: Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 34: 235-239, 2004.
17. Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F and Viale G: Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118: 817-820, 2002.
18. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ and Greipp PR: Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8: 2210-2216, 2002.
19. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F and Dammacco F: A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88: 176-185, 2003. (Pubitemid 37101495)
20. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR and Rajkumar SV: Expression of VEGF and its receptors by myeloma cells. Leukemia 17: 2025-2031, 2003. (Pubitemid 37322133)
21. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D and Anderson KC: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 103: 19478-19483, 2006.
22. Marković O, Marisavljević D, Cemerikić V, Vidović A, Perunicić M, Todorović M, Elezović I and Colović M: Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Med Oncol 25: 451-457, 2008.
23. Ribas C, Colleoni GW, Silva MR, Carregoza MJ and Bordin JO: Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol 73: 311-317, 2004. (Pubitemid 39349911)
24. Shin DH, Chun YS, Lee DS, Huang LE and Park JW: Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111: 5258-5259, 2008.
25. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V and Giuliani N: The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma- induced angiogenesis. Blood 110: 4464-4475, 2007.
26. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dörken B and Bargou RC: PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 18: 1883-1890, 2004.
27. Frost P, Shi Y, Hoang B and Lichtenstein A: AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26: 2255-2262, 2007. (Pubitemid 46572812)
28. Otsuki T, Kurebayashi J, Ohkubo S, Uno M, Fujii T, Sakaguchi H, Hatayama T, Takata A, Tsujioka T, Sugihara T and Hyodoh F: Expression of HER family receptors and effects of anti-HER2- antibody on human myeloma cell lines. Int J Oncol 23: 1135-1141, 2003.